TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Actinium
/ therapeutic use
Alpha Particles
/ therapeutic use
Animals
Antibodies, Monoclonal
/ chemistry
Antigens, Neoplasm
/ metabolism
Cell Line, Tumor
Cell Transformation, Neoplastic
Female
Heterocyclic Compounds, 1-Ring
/ chemistry
Humans
Isotope Labeling
Mice
Molecular Targeted Therapy
Ovarian Neoplasms
/ immunology
Radioimmunotherapy
/ methods
Tissue Distribution
225Ac
TAG-72
ovarian cancer
radioimmunotherapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
07
02
2020
accepted:
27
05
2020
pubmed:
6
7
2020
medline:
27
4
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Radioimmunotherapy, an approach using radiolabeled antibodies, has had minimal success in the clinic with several β-emitting radionuclides for the treatment of ovarian cancer. Alternatively, radioimmunotherapy with α-emitters offers the advantage of depositing much higher energy over shorter distances but was thought to be inappropriate for the treatment of solid tumors, for which antibody penetration is limited to a few cell diameters around the vascular system. However, the deposition of high-energy α-emitters to tumor markers adjacent to a typical leaky tumor vascular system may have large antitumor effects at the tumor vascular level, and their reduced penetration in normal tissue would be expected to lower off-target toxicity.
Identifiants
pubmed: 32620701
pii: jnumed.120.243394
doi: 10.2967/jnumed.120.243394
pmc: PMC9364881
doi:
Substances chimiques
Actinium-225
0
Antibodies, Monoclonal
0
Antigens, Neoplasm
0
Heterocyclic Compounds, 1-Ring
0
tumor-associated antigen 72
0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
Actinium
NIK1K0956U
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-61Subventions
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238429
Pays : United States
Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
Front Oncol. 2013 Aug 15;3:211
pubmed: 23967403
Blood. 2013 May 2;121(18):3759-67
pubmed: 23471305
J Nucl Med. 1990 Jul;31(7):1191-8
pubmed: 2362198
Curr Radiopharm. 2011 Oct;4(4):306-20
pubmed: 22202153
Cancer Res. 2003 Aug 15;63(16):5084-90
pubmed: 12941838
Cancer Sci. 2009 Dec;100(12):2426-30
pubmed: 19793083
Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2436-46
pubmed: 20644928
Bioconjug Chem. 2008 Jan;19(1):89-96
pubmed: 17988078
J Natl Cancer Inst. 1986 Jun;76(6):995-1006
pubmed: 3520078
Gynecol Oncol. 2003 Sep;90(3):593-6
pubmed: 13678730
Cancer Biother Radiopharm. 2002 Apr;17(2):219-31
pubmed: 12030116
J Nucl Med. 2010 Feb;51(2):311-28
pubmed: 20080889
J Clin Oncol. 2006 Oct 10;24(29):4699-707
pubmed: 16966687
Cancer Res. 1986 Feb;46(2):850-7
pubmed: 3940648
Cancer Res. 2009 Dec 1;69(23):8941-8
pubmed: 19920193
Cancer Res. 1988 Aug 15;48(16):4588-96
pubmed: 3396010
Clin Cancer Res. 2002 Sep;8(9):2806-11
pubmed: 12231520
Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S89-95
pubmed: 16979448
Cancer. 1994 Feb 1;73(3 Suppl):1057-66
pubmed: 8306248
Int J Gynecol Pathol. 1992 Jul;11(3):216-20
pubmed: 1399229
Ann Oncol. 2005 May;16(5):749-55
pubmed: 15817604
Cancer Lett. 2007 Jun 28;251(2):247-57
pubmed: 17210225
Appl Radiat Isot. 2013 Jul;77:32-7
pubmed: 23511775
Phys Med Biol. 2011 Feb 7;56(3):721-33
pubmed: 21220845
J Nucl Med. 2013 Sep;54(9):1597-604
pubmed: 24003167
Gynecol Oncol. 1997 Apr;65(1):94-101
pubmed: 9103398
Clin Cancer Res. 2004 Oct 15;10(20):6985-92
pubmed: 15501978
J Nucl Med. 2016 Oct;57(10):1576-1582
pubmed: 27127217
Cancer Biol Ther. 2008 Jan;7(1):76-80
pubmed: 18347423
Clin Nucl Med. 1995 Mar;20(3):230-6
pubmed: 7750217
Prostate. 2004 Feb 1;58(2):145-55
pubmed: 14716739